Erosive esophagitis is more than just a medical term—it’s a painful reality for millions of Indians. Often caused by acid reflux, it can make eating, sleeping, and even talking a challenge. But now, there’s a promising new treatment that could change how we manage this condition: FEXUCLUE®, a novel acid blocker introduced by Sun Pharma.
Let’s explore the journey of this new drug and why it’s making headlines across the country.
What is FEXUCLUE and Why is it a Big Deal?
FEXUCLUE®, containing Fexuprazan, is a Potassium-Competitive Acid Blocker (PCAB). This means it works differently from traditional acid-reducing drugs. Available in 40 mg tablets, it’s approved for treating all grades of erosive esophagitis in adults.
But that’s not all. FEXUCLUE is also being studied for preventing NSAID-induced ulcers and gastritis, making it a potential multi-purpose acid treatment in the future.
The Science Behind the Promise
A Phase 3 clinical study conducted in India showed impressive results. Over 95% of patients experienced healing within just eight weeks. This wasn’t just a feeling—healing was confirmed through endoscopy, the gold standard in diagnosis. Even better? The treatment was well tolerated, with minimal side effects reported.
Also Read: Texas Measles Outbreak Kills Second Child Amid Vaccine Backlash
A Global Partnership with Local Impact
Sun Pharma didn’t create this drug alone. It has entered into an exclusive partnership with Daewoong Pharmaceutical, a respected biopharma company from South Korea. Under the agreement, Sun Pharma gets the rights to manufacture and commercialize FEXUCLUE in India, while Daewoong will receive upfront payments, milestone bonuses, and royalties.
This collaboration is a perfect example of how international innovation can meet local healthcare needs.
What Sun Pharma Has to Say
Kirti Ganorkar, CEO of Sun Pharma’s India Business, expressed the company’s strong intent:
“Erosive esophagitis is a serious condition that greatly affects patients’ quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE® is a best-in-class treatment option with the potential to bridge this gap.”
For Sun Pharma, this isn’t just another product. It’s part of a bigger commitment to introduce innovative, patient-focused medicines to the Indian market.
The Bigger Picture
Sun Pharma is already India’s top pharmaceutical company, with a global presence in both generic and specialty medicines. In Q3 FY25, the company posted a 15% rise in net profit, reaching Rs 2,903 crore, while revenue grew by over 10%. Despite a 3.47% dip in its stock price recently, the company continues to lead from the front with game-changing products like FEXUCLUE.
What This Means for Patients
Acid reflux, GERD, and related disorders affect the daily lives of countless people. With FEXUCLUE, these individuals might finally find fast, effective, and well-tolerated relief. Whether it’s reducing pain, improving sleep, or preventing long-term damage, FEXUCLUE offers hope wrapped in a small tablet.
This launch is not just another pharma announcement—it’s a turning point in digestive health in India.
